Polyfunctional, pathogenic CD161+ Th17 lineage cells are resistant to regulatory T cell-mediated suppression in the context of autoimmunity

Journal of Immunology

Volumn 195, Issue 2, 2015, Pages 528-540

  Basdeo, Sharee A ^a   Moran, Barry ^a   Cluxton, Deborah ^a   Canavan, Mary ^b   McCormick, Jennifer ^b   Connolly, Mary ^b   Orr, Carl ^b   Mills, Kingston H G ^a   Veale, Douglas J ^b   Fearon, Ursula ^b   Fletcher, Jean M ^a,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; STAT3 PROTEIN; APYRASE; CD39 ANTIGEN; CTLA4 PROTEIN, HUMAN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; KLRB1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY B; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CD161+ TH17 LINEAGE CELL; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MALE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM; TELOMERE; TH17 CELL; VERY ELDERLY; CELL LINEAGE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; JOINT; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; APYRASE; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CELL LINEAGE; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; JOINTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL FLUID; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84936818691     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402990     Document Type: Article

References (66)

1. Sempere-Ortells, J. M., V. Perez-Garćia, G. Maŕin-Alberca, A. Peris-Pertusa, J. M. Benito, F. M. Marco, J. J. Zubcoff, and F. J. Navarro-Blasco. 2009. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity 42: 636-645.
2. Cao, D., V. Malmström, C. Baecher-Allan, D. Hafler, L. Klareskog, and C. Trollmo. 2003. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur. J. Immunol. 33: 215-223.
3. Raghavan, S., D. Cao, M. Widhe, K. Roth, J. Herrath, M. Engström, G. Roncador, A. H. Banham, C. Trollmo, A. I. Catrina, and V. Malmström. 2009. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann. Rheum. Dis. 68: 1908-1915.
4. van Amelsfort, J. M., K. M. Jacobs, J. W. Bijlsma, F. P. Lafeber, and L. S. Taams. 2004. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50: 2775-2785.
5. Cao, D., R. van Vollenhoven, L. Klareskog, C. Trollmo, and V. Malmström. 2004. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 6: R335-R346.
6. Flores-Borja, F., E. C. Jury, C. Mauri, and M. R. Ehrenstein. 2008. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 105: 19396-19401.
7. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285.
8. Xiao, H., S. Wang, R. Miao, and W. Kan. 2011. TRAIL is associated with impaired regulation of CD4+CD25-T cells by regulatory T cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31: 1112-1119.
9. Beavis, P. A., B. Gregory, P. Green, A. P. Cribbs, A. Kennedy, P. Amjadi, A. C. Palfreeman, M. Feldmann, and F. M. Brennan. 2011. Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc. Natl. Acad. Sci. USA 108: 16717-16722.
10. Astry, B., E. Harberts, and K. D. Moudgil. 2011. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J. Interferon Cytokine Res. 31: 927-940.
11. Tran, C. N., S. K. Lundy, and D. A. Fox. 2005. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 12: 183-189.
12. Cope, A. P. 2008. T cells in rheumatoid arthritis. Arthritis Res. Ther. 10(Suppl 1): S1.
13. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177.
14. Lubberts, E., M. I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C. J. Coenen-de Roo, L. A. Joosten, and W. B. van den Berg. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50: 650-659.
15. Metawi, S. A., D. Abbas, M. M. Kamal, and M. K. Ibrahim. 2011. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin. Rheumatol. 30: 1201-1207.
16. Moran, E. M., R. Mullan, J. McCormick, M. Connolly, O. Sullivan, O. Fitzgerald, B. Bresnihan, D. J. Veale, and U. Fearon. 2009. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res. Ther. 11: R113.
17. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
18. Kellner, H. 2013. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther. Adv. Musculoskelet. Dis. 5: 141-152.
19. Zhou, L., M. M. Chong, and D. R. Littman. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655.
20. Hirahara, K., A. Poholek, G. Vahedi, A. Laurence, Y. Kanno, J. D. Milner, and J. J. O'Shea. 2013. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J. Allergy Clin. Immunol. 131: 1276-1287.
21. Magombedze, G., P. B. Reddy, S. Eda, and V. V. Ganusov. 2013. Cellular and population plasticity of helper CD4(+) T cell responses. Front. Physiol. 4: 206.
22. Annunziato, F., L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani. 2012. Defining the human T helper 17 cell phenotype. Trends Immunol. 33: 505-512.
23. Hirota, K., J. H. Duarte, M. Veldhoen, E. Hornsby, Y. Li, D. J. Cua, H. Ahlfors, C. Wilhelm, M. Tolaini, U. Menzel, et al. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12: 255-263.
24. Nistala, K., S. Adams, H. Cambrook, S. Ursu, B. Olivito, W. de Jager, J. G. Evans, R. Cimaz, M. Bajaj-Elliott, and L. R. Wedderburn. 2010. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci. USA 107: 14751-14756.
25. Lee, Y. K., H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
26. Lexberg, M. H., A. Taubner, A. Förster, I. Albrecht, A. Richter, T. Kamradt, A. Radbruch, and H. D. Chang. 2008. Th memory for interleukin-17 expression is stable in vivo. Eur. J. Immunol. 38: 2654-2664.
27. Maggi, L., V. Santarlasci, M. Capone, M. C. Rossi, V. Querci, A. Mazzoni, R. Cimaz, R. De Palma, F. Liotta, E. Maggi, et al. 2012. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur. J. Immunol. 42: 3180-3188.
28. Cosmi, L., R. De Palma, V. Santarlasci, L. Maggi, M. Capone, F. Frosali, G. Rodolico, V. Querci, G. Abbate, R. Angeli, et al. 2008. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205: 1903-1916.
29. Annunziato, F., L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani. 2013. Main features of human T helper 17 cells. Ann. N. Y. Acad. Sci. 1284: 66-70.
30. Chalan, P., B. J. Kroesen, K. S. van der Geest, M. G. Huitema, W. H. Abdulahad, J. Bijzet, E. Brouwer, and A. M. Boots. 2013. Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis. PLoS ONE 8: e79370.
31. Cosmi, L., R. Cimaz, L. Maggi, V. Santarlasci, M. Capone, F. Borriello, F. Frosali, V. Querci, G. Simonini, G. Barra, et al. 2011. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum. 63: 2504-2515.
32. Kleinschek, M. A., K. Boniface, S. Sadekova, J. Grein, E. E. Murphy, S. P. Turner, L. Raskin, B. Desai, W. A. Faubion, R. de Waal Malefyt, et al. 2009. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206: 525-534.
33. Annibali, V., G. Ristori, D. F. Angelini, B. Serafini, R. Mechelli, S. Cannoni, S. Romano, A. Paolillo, H. Abderrahim, A. Diamantini, et al. 2011. CD161(high) CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain 134: 542-554.
34. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al; International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862.
35. Miossec, P. 2003. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48: 594-601.
36. Griffin, G. K., G. Newton, M. L. Tarrio, D. X. Bu, E. Maganto-Garcia, V. Azcutia, P. Alcaide, N. Grabie, F. W. Luscinskas, K. J. Croce, and A. H. Lichtman. 2012. IL-17 and TNF- A sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J. Immunol. 188: 6287-6299.
37. Liu, B., W. Tan, A. Barsoum, X. Gu, K. Chen, W. Huang, A. Ramsay, J. K. Kolls, and P. Schwarzenberger. 2010. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement. Exp. Hematol. 38: 877-884 e871.
38. Aletaha, D., T. Neogi, A. J. Silman, J. Funovits, D. T. Felson, C. O. Bingham, III, N. S. Birnbaum, G. R. Burmester, V. P. Bykerk, M. D. Cohen, et al. 2010. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62: 2569-2581.
39. Roederer, M., J. L. Nozzi, and M. C. Nason. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
40. Fearon, U., R. Mullan, T. Markham, M. Connolly, S. Sullivan, A. R. Poole, O. FitzGerald, B. Bresnihan, and D. J. Veale. 2006. Oncostatin M induces an-giogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum. 54: 3152-3162.
41. Taams, L. S., J. Smith, M. H. Rustin, M. Salmon, L. W. Poulter, and A. N. Akbar. 2001. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur. J. Immunol. 31: 1122-1131.
42. Filer, A. 2013. The fibroblast as a therapeutic target in rheumatoid arthritis. Curr. Opin. Pharmacol. 13: 413-419.
43. Buckley, C. D. 2011. Why does chronic inflammation persist: An unexpected role for fibroblasts. Immunol. Lett. 138: 12-14.
44. Filer, A., G. Parsonage, E. Smith, C. Osborne, A. M. Thomas, S. J. Curnow, G. E. Rainger, K. Raza, G. B. Nash, J. Lord, et al. 2006. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. Arthritis Rheum. 54: 2096-2108.
45. Buckley, C. D., D. Pilling, J. M. Lord, A. N. Akbar, D. Scheel-Toellner, and M. Salmon. 2001. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 22: 199-204.
46. Ritchlin, C. 2000. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2: 356-360.
47. Shigeyama, Y., T. Pap, P. Kunzler, B. R. Simmen, R. E. Gay, and S. Gay. 2000. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43: 2523-2530.
48. Goodman, W. A., A. B. Young, T. S. McCormick, K. D. Cooper, and A. D. Levine. 2011. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186: 3336-3345.
49. Schust, J., B. Sperl, A. Hollis, T. U. Mayer, and T. Berg. 2006. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13: 1235-1242.
50. Ng, C. T., M. Biniecka, A. Kennedy, J. McCormick, O. Fitzgerald, B. Bresnihan, D. Buggy, C. T. Taylor, J. O'Sullivan, U. Fearon, and D. J. Veale. 2010. Synovial tissue hypoxia and inflammation in vivo. Ann. Rheum. Dis. 69: 1389-1395.
51. Dang, E. V., J. Barbi, H. Y. Yang, D. Jinasena, H. Yu, Y. Zheng, Z. Bordman, J. Fu, Y. Kim, H. R. Yen, et al. 2011. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-784.
52. Shi, L. Z., R. Wang, G. Huang, P. Vogel, G. Neale, D. R. Green, and H. Chi. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208: 1367-1376.
53. Ben-Shoshan, J., S. Maysel-Auslender, A. Mor, G. Keren, and J. George. 2008. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur. J. Immunol. 38: 2412-2418.
54. Clambey, E. T., E. N. McNamee, J. A. Westrich, L. E. Glover, E. L. Campbell, P. Jedlicka, E. F. de Zoeten, J. C. Cambier, K. R. Stenmark, S. P. Colgan, and H. K. Eltzschig. 2012. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. USA 109: E2784-E2793.
55. Fletcher, J. M., R. Lonergan, L. Costelloe, K. Kinsella, B. Moran, C. O'Farrelly, N. Tubridy, and K. H. Mills. 2009. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183: 7602-7610.
56. Wehrens, E. J., G. Mijnheer, C. L. Duurland, M. Klein, J. Meerding, J. van Loosdregt, W. de Jager, B. Sawitzki, P. J. Coffer, B. Vastert, et al. 2011. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118: 3538-3548.
57. Haufe, S., M. Haug, C. Schepp, J. Kuemmerle-Deschner, S. Hansmann, N. Rieber, N. Tzaribachev, T. Hospach, J. Maier, G. E. Dannecker, and U. Holzer. 2011. Impaired suppression of synovial fluid CD4+CD25-T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum. 63: 3153-3162.
58. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Filì, S. Ferri, F. Frosali, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861.
59. Crome, S. Q., B. Clive, A. Y. Wang, C. Y. Kang, V. Chow, J. Yu, A. Lai, A. Ghahary, R. Broady, and M. K. Levings. 2010. Inflammatory effects of ex vivo human Th17 cells are suppressed by regulatory T cells. J. Immunol. 185: 3199-3208.
60. Gao, W., J. McCormick, M. Connolly, E. Balogh, D. J. Veale, and U. Fearon. 2015. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann. Rheum. Dis. 74: 1275-1283.
61. El-Behi, M., B. Ciric, H. Dai, Y. Yan, M. Cullimore, F. Safavi, G. X. Zhang, B. N. Dittel, and A. Rostami. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12: 568-575.
62. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORgt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neu-roinflammation. Nat. Immunol. 12: 560-567.
63. Behrens, F., P. P. Tak, M. Ostergaard, R. Stoilov, P. Wiland, T. W. Huizinga, V. Y. Berenfus, S. Vladeva, J. Rech, A. Rubbert-Roth, et al. 2015. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann. Rheum. Dis. 74: 1058-1064.
64. Campbell, I. K., A. Bendele, D. A. Smith, and J. A. Hamilton. 1997. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 56: 364-368.
65. Hot, A., V. Lenief, and P. Miossec. 2012. Combination of IL-17 and TNFa induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann. Rheum. Dis. 71: 768-776.
66. Hohensinner, P. J., J. J. Goronzy, and C. M. Weyand. 2011. Telomere dysfunction, autoimmunity and aging. Aging Dis. 2: 524-537.